Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
J Menis1, C Twelves21Department of Oncology, University Hospital Santa Maria della Misericordia, Udine, Italy; 2Leeds Cancer Research UK Centre, University of Leeds and St James's Institute of Oncology, Leeds, UKAbstract: Although metastatic breast cancer remains essentially incurable, m...
Guardado en:
Autores principales: | Twelves C, Menis J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a5e9b2585b654bbd9e10446da9899e17 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Corrigendum
por: Menis J, et al.
Publicado: (2011) -
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Tomás Pascual, et al.
Publicado: (2021) -
Taxanes in the elderly patient with metastatic breast cancer
por: Yardley DA
Publicado: (2015) -
Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan P, et al.
Publicado: (2021) -
Comprehensive characterization of distinct genetic alterations in metastatic breast cancer across various metastatic sites
por: Soojin Cha, et al.
Publicado: (2021)